Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-034972
Filing Date
2025-03-06
Accepted
2025-03-06 18:02:17
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11362
2 EX-1 ck0001669811-ex1.pdf EX-1 74066
  Complete submission text file 0000950170-25-034972.txt   115193
Mailing Address 228 HAMILTON AVENUE, 3RD FLOOR PALO ALTO CA 94301
Business Address 228 HAMILTON AVENUE, 3RD FLOOR PALO ALTO CA 94301 650-798-5495
TCG Crossover GP I, LLC (Filed by) CIK: 0001839947 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 2656 STATE STREET CARLSBAD CA 92008
Business Address 2656 STATE STREET CARLSBAD CA 92008 (619) 728-4760
Tyra Biosciences, Inc. (Subject) CIK: 0001863127 (see all company filings)

EIN.: 831476348 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92865 | Film No.: 25716664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)